



World Congress Insulin Resistance **DIABETES & CARDIOVASCULAR DISEASE**



JOINTLY PROVIDED































It is my pleasure to welcome you to the 21st Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC): Exploring New Frontiers in Metabolism — Tomorrow's Clinical Science Today.

The 21st Annual WCIRDC will be held on December 7—9, 2023, at the Hilton Universal City, Los Angeles. This CME/MOC conference will be available On-Demand for 90 days following the meeting.

Since its inception, the congress has become the premier global meeting dedicated to metabolism- obesity, diabetes, lipids, HTN, CKD, CVD, HF, and NAFLD. This is the only conference of its size that incorporates clinical, translational and basic science. It offers an exclusive platform allowing professionals, clinicians and researchers to exchange ideas and collaborate on emerging scientific and management concepts.

The WCIRDC faculty consists of globally acclaimed experts who link research to clinical practice in a bench-to-bedside-to-bench approach which is unique to this state-of-the-art program.

We are proud to honor Professor Paul Zimmet, MD, PhD with the prestigious "Gerald Reaven Distinguished Leader in Insulin Resistance Award", recognizing his exceptional contributions to the field. Dr Zimmer's keynote lecture: Insulin Resistance and its outcomes in T2DM: A Historical and Epidemiological Perspective.

This year's conference will cover a wide range of topics including Lipidology, Cardiomyopathy & Heart Failure, Contemporary Management Of Obesity And Diabetes, The Multiple Faces Of Insulin Resistance, Women's Health State Of The Art Approach To Kidney, and Heart Disease, a joint session with the journal Metabolism; and much more encompassing the multifaceted realm of metabolic medicine. Distinguished experts are poised to unveil groundbreaking perspectives fostering an environment conducive to collaborative learning and professional growth.

Clinical workshops & meet-the-expert small groups sessions will provide attendees with a rare opportunity to personally interact with esteemed leaders in an intimate setting.

The Congress has a strong and highly successful abstracts program. Abstracts will be published in Metabolism Clinical and Experimental- IF 13.93 EIC Christos S. Mantzoros, MD, PhD, DSc.

. The 21st WCIRDC will feature a robust Poster Hall, Oral Abstract Presentations, an attractive Exhibit Hall, and Industry Supported non-CME programs featuring important new scientific concepts with some of the world's best-known educators. I look forward to you attending this exciting conference on December 7–9, 2023, at Hilton Universal City Los Angeles, California. We hope to see you there.

Best regards,



Best regards,

Yehuda Handelsman, MD Chair & Program Director

Scientific Organizing Committee - International Committee for Insulin Resistance - ICIR

Yehuda Handelsman, MD Chair Tarzana, CA

Richard N. Bergman, PhD Los Angeles, CA

Zachary T. Bloomgarden, MD New York, NY

Matthew J. Budoff, MD Los Angeles, CA

Sonia Caprio, MD New Haven, CT

Robert J. Chilton, DO San Antonio, TX

Kenneth Cusi, MD Gainesville, FL

Jaime A. Davidson, MD Dallas, TX

Ralph A. DeFronzo, MD San Antonio, TX

Vivian A. Fonseca, MD New Orleans, LA

W. Timothy Garvey, MD Birmingham, AL

Peter J. Grant, MD Leeds, UK

Jennifer B. Green, MD Durham, NC

George Grunberger, MD Bloomfield Hills, MI

Chris K. Guerin, MD Oceanside, CA

Ania M. Jastreboff, MD, PhD New Haven, CT

Paul S. Jellinger, MD Hollywood, FL

Samuel Klein, MD St. Louis, MO

Mikhail N. Kosiborod, MD Kansas City, MO

Ronald M. Krauss, MD Berkeley, CA

Norman E. Lepor, MD

Los Angeles, CA Derek LeRoith, MD, PhD

New York, NY Philip Levy, MD

Phoenix, AZ

Ildiko Lingvay, MD, MPH, MSCS Dallas, TX

Christos S. Mantzoros, MD, PhD Harvard, MA

Nikolaus Marx, MD Aachen, GER

Tracey L. McLaughlin, MD Stanford, CA

Christian W. Mende, MD La Jolla, CA

Erin D. Michos, MD, MHS Baltimore, MD

Jorge Plutzky, MD Boston, MA

Richard E. Pratley, MD Orlando, FL

Arun J. Sanyal, MD Richmond, VA

Philipp E. Scherer, PhD Dallas, TX

Alan R. Sinaiko, MD Minneapolis, MN

Bart Staels, PhD Lille. FR

Pam R. Taub, MD San Diego, CA

Muthiah Vaduganathan, MD, MPH Boston, MA

Matthew R. Weir, MD Baltimore, MD

Paul Zimmet, MD, PhD Melbourne, AUS

The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 21st year, stands as a distinctive and vibrant multidisciplinary CME conference. Serving as the paramount global assembly dedicated to diabetes, obesity, lipids, cardiovascular-kidney, and liver diseases.

The Congress intricately weaves together basic research and clinical practice in pursuit of our guiding theme: Exploring New Frontiers in Metabolism — Tomorrow's Clinical Science Today.

Participants are able to earn up to 26.75 CME & ABIM-MOC credits.

The WCIRDC program features a unique convergence of basic and clinical science. For over two decades, it has convened physicians, clinicians, researchers, and other healthcare professionals into an international arena, crafting an exclusive program that seamlessly bridges the latest advancements from

The program is designed to evaluate both clinical

and basic science aspects of diabetes, obesity, CVD

aut, the brain, the kidney and the heart. The goal

is to understand pathophysiology and to develop

appropriate comprehensive clinical management

Upon completion of this meeting, participants should

Discuss the effects of insulin resistance on the

Describe the relationship between diabetes,

obesity, kidney disease, and heart disease

heart, kidney, and liver

plans.

be able to:

and CKD, focusing on insulin resistance, incretins, the

PROGRAM DESCRIPTION

bench-to-bedside-to-bench. Often resonating with the words, "I heard it first at the WCIRDC," the program provides an unparalleled opportunity for attendees to directly engage with distinguished global faculty, within an intimate setting, propelling explorations into the most current understanding of metabolic diseases and the unfolding emerging therapeutic approaches.

Since the seminal work of Dr. Gerald Reaven, crystallizing the interplay of insulin resistance, diabetes, obesity, and cardiovascular disease, the congress's scope has expanded. It now encompasses domains such as the kidney, liver, brain, bone, cancer, and beyond. The congress agenda includes dyslipidemia, atherosclerosis, hypertension, hypercoagulation, and inflammation. It also underscores the intricate interplay between Diabetes-Cardio-Renal and Metabolic Diseases. The program will cover updates on pharmaceutical interventions, including incretins- GLP1 ra and dual agonists, SGLT218. SGLT2/1i, PCSK9 i, MRA, bempedoic acid and IPE, will be illuminated. The aim is to foster an in-depth

understanding of state-of-the-art pathophysiology, novel medical interventions, and the development of comprehensive clinical management strategies.

To bridge the gap between research and clinical practice, live Q&A and panel discussions will follow each session, exploring their implications in clinical scenarios. Enhanced interaction with faculty and fellow attendees will be facilitated through extended breaks and social events.

The Congress garners cutting-edge abstracts from both emerging researchers and renowned leaders across the globe. The best abstracts will be presented orally. There will be a key note presentation by professor Paul Zimmet, the recipient of the Gerald Reaven Distinguished Leader Award. Clinical workshops and meet the experts sessions allow for small groups learning and intimate face to face interaction with some of the best known leaders.

PROGRAM OBJECTIVES

- Implement best practices for the prevention and management of CKD, HF, and CVD
- Describe the recommended uses of SGLT2 inhibitors for the treatment of HF
- Describe the contemporary role of SGLT2 inhibitors in CKD with and without diabetes as consistent with approved indications
- Describe the benefits of GLP1-RAs in patients with ASCVD or at risk of ASCVD events
- Evaluate the evidence supporting the use of new and emerging therapies to reduce cardiovascular mortality in patients with cardiometabolic disease

- Explain the roles of diabetes and insulin resistance in the development of CKD, HF, and CVD
- Evaluate the impact on clinical practice of new CVOTs in patients with diabetes and other cardiometabolic diseases
- Design therapeutic regimens for patients with multiple cardiorenal and metabolic disorders that capitalize on agents with broad effects across the spectrum of these comorbidities
- Utilize technology to enhance the effectiveness of therapeutics

TARGET AUDIENCE

This educational initiative is designed for endocrinologists, cardiologists, nephrologists, family physicians, internists, diabetologists, gastroenterologists, pediatricians, OB/GYNs, researchers, nurse practitioners, physician assistants, dieticians, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity. CVD. CKD. HF. and associated conditions, as well as the effect of these conditions on health and society.



THURSDAY, DECEMBER 7

6:45 am Pre-Registration

7:00 am — 8:00 am **EXHIBIT HALL OPENS** | Coffee will be served

7:00 am — 7:45 am Breakfast Session Non-CME Education Product Theater Hall

BMF-219: An Oral Menin Inhibitor in Clinical Development as a Short-term Therapy to Address the Root Cause of Diabetes, Beta-cell Dysfunction

Supported by **Biomea Fusion**

Priyanka Somanath, PhD



Endothelium and Cardiometabolic Disorders

Thomas Butler, MS, MBA



Rohit N. Kulkarni, MD, Phi



Juan Frias, MD



8:00 am — 8:15 am Welcome & Introduction | Pre-CME Questions Yehuda Handelsman, MD

Jession i	Lincolnelloni una Cardionierabone Disorders	
8:15 am — 9:30 am	Chairs: Vivian A. Fonseca, MD ● Derek LeRoith, MD, PhD	
8:15 am	The Effects of RYGB on Cholesterol and Bile Acid Metabolism in Humans	Bart Staels, PhD
8:35 am	Endothelial-Mesenchymal Transition in Cardiovascular Disease (EndMT)	Jorge Plutzky, MD
8:55 am	The Role of SGLTx in ACS, A. Fib & Metabolism- A Translational Approach	Robert J. Chilton, DO

Session 2	ASCVD Epidemiology, Pathophysiology & Management
9:30 am — 10:45 am	Chairs: Ronald M. Krauss, MD ● Robert J. Chilton, MD

9:30 am Importance of Cardiovascular Risk Assessment and Multiple Risk Factor Control in Diabetes
9:50 am Common Molecular Mechanisms Drive Cardiometabolic and Vascular Diseases Outcomes- Clinical Implications
10:10 am The Relationships Between HDL Dysfunction, Genetic Very Small LDL, CAC and Insulin Resistance
10:30 am – 10:45 am Panel Discussion and Q&A

10:45 am — 11:15 am REFRESHMENT BREAK at the Exhibit Hall

Session 3	Lipidology Toward 2024 - Panel Session
11:15 am — 12:10 pm	Chairs: Erin D. Michos, MD, MHS • Chris K. Guerin, MD

Panel Discussion and Q&A

11:15 am The Role of the Mitochondrial/ER Axis in Cholesterol Metabolism and Statin Myopathy

Lp(a), CETP / BA-CLEAR / Very High HDL

Discussions and Q&A

Ronald M. Krauss, MD Seth S. Martin, MD, MHS Arthur S. Agatston, MD

12:10 pm

Session 1

9:15 am - 9:30 am

Session 4 Concurrent Sessions: Meet the Experts

12:15 pm - 1:00 pm

Ralph A. DeFronzo, MD Insulin Resistance — Intensive Management of DM Mandarin AB
Vivian A. Fonseca, MD DCRM Risk Prediction Sierra CD (Lecture Hall)

Jennifer B. Green, MD CKD Emerging Strategies Club
Yehuda Handelsman, MD Technology in DM and CRM Salon 6AB

1:00 pm — 2:00 pm **LUNCH BREAK**

1:10 pm — 1:55 pm Lunch Session Non-CME Product Theater Hall

Jardiance® (empagliflozin) tablets: A Peer Review of the Latest Clinical Data and Dosing Recommendations

Supported by **Boehringer Ingelheim—Lilly**

Christian Mende, MD



THURSDAY, DECEMBER 7 (Cont.)

Session 5 2:00 pm — 2:50 pm	Metabolic Science Chairs: Richard N. Bergman, PhD ● Phillip E. Scherer, PhD	
2:20 pm 2:20 pm 2:40 pm — 2:50 pm	Genome- Proteome- Phenome & Mendelian Randomization Studies, Elucidating Novel Pathways and Treatments- Clinical Implication in Cardiometabolic Disorders The Role of mRNA Modifications in the Regulation of Metabolism Panel Discussion and Q&A	Christos S. Mantzoros, MD, PhD Rohit N. Kulkarni, MD, PhD
Session 6 2:50 pm — 3:40 pm	The Future of HTN Chairs: Pam R. Taub, MD • Chris W. Mende, MD	
2:50 pm 3:10 pm 3:30 pm — 3:40 pm	Refractory HTN and New Drugs & Procedures in the Future Need for New Agents to Overcome Healthcare Disparity in Hypertension Panel Discussion and Q&A	Norman E. Lepor, MD Keith C. Ferdinand, MD
Session 7 3:40 pm — 4:10 pm	DCRM 2.0 — Update and Global Transformation Chairs: Richard E. Pratley, MD • Matthew R. Weir, MD	
3:40 pm 3:55 pm — 4:10 pm 4:10 pm — 4:40 pm	DCRM 2.0 - Diabetes CardioRenal & Metabolic Diseases- Update & Global Panel Discussion and Q&A REFRESHMENT BREAK at the Exhibit Hall	Yehuda Handelsman, MD
Session 8 5:00 pm — 6:35 pm	Insulin Resistance, Diabetes, and Beyond Chairs: Jennifer B. Green, MD • Jorge Plutzky, MD	
4:40 pm 5:00 pm 5:20 pm 5:40 pm 6:00pm 6:20 pm — 6:35 pm	Brain HDL and Alzheimer's Disease: Toward Therapeutic Applications Pulmonary Disease in Diabetes- Another Final Frontier? Contemporary Nomenclature of Fatty Liver Disease Impact on Diagnosis and Management Vascular Aging in CKD Management of Diabetes in Patients with Cancer Addressing Impact of Cancer Therapy Overcoming Treatment Challenges: Management of Patients with Diabetes and Cancer Panel Discussion and Q&A	Hussein Yassine, MD Peter J. Grant, MD Rohit Loomba, MD, MHSc Matthew R. Weir, MD Emily J. Gallagher, MD, PhD

6:35pm - 7:30 pm WELCOME & POSTER RECEPTION AT EXHIBIT HALL Cocktails and hors d'oeuvres will be served

7:30 pm — 9:15 pm	Dinner CME Symposium	Supported by AstraZeneca
	Winning The Trifecta of Diabetes, Heart and Kidney D	iseases
v. Demail	Chairs: Yehuda Handelsman, MD ● Muthiah Vaduganathan, M), MPH
	7:30 pm Introduction & Pre-CME Questions	Muthiah Vaduganathan, MD, MPH
	7:40 pm Early Intervention in Diabetes Addressing Patho	ohysiology in Preventing Comorbidities Vivian A. Fonseca, MD
	8:00 pm SGLT2i Effects Across The Spectrum of CKD And	Aultiple Populations Peter Rossing, MD
	8:20 pm Impact of SGLT2i on HF Outcomes in Various Po	ulations & The Range of LVEF Muthiah Vaduganathan, MD, MPH
	8:40 pm Panel Discussion and Q&A: Changing the Traject	ory of Heart Failure and CKD,
	Implementing Guidelines Directed Medical There	ру
	Panel: Vivian A. Fonseca, MD ● Christian W. Mer	de, MD ● Erin D. Michos, MD, MHS
	Peter Rossing, MD ● Muthiah Vaduganathan, MI), MPH
	Moderator: Yehuda Handelsman, MD	
	9:10 pm Concluding Remarks & Post-CME Questions	
	9:15 pm Adjourn	



FRIDAY, DECEMBER 8

Rohit Kohli, MBBS, MS

7:00 am Registration

7:00 am - 8:00 am **EXHIBIT HALL OPENS**

7:00 am - 7:45 am Non-CME **Product Theater Hall Breakfast Session**

The Dual Dilemma: Navigating Cardiorenal Risk in CKD Associated with T2D

Dharmesh S. Patel, MD, MBBS Supported by **Bayer**

8:00 am - 8:15 am Summary of Day 1 and Pre-CME Questions Zachary T. Bloomgarden, MD

Session 9 Women's Health

8:15 am - 9:05 am Chairs: Ania M. Jastreboff, MD • Pam R. Taub, MD

8:15 am Infertility, Assisted Reproductive Technology, and Cardiovascular Risk Erin D. Michos, MD, MHS 8:35 am Sex Differences in Cardiovascular Risk Associated with Pre, Newly Diagnosed, and Undiagnosed-Diabetes Vivian A. Fonseca, MD

Panel Discussion and Q&A 8:55 am - 9:05 am

Session 10 The Multiple Faces of Insulin Resistance

9:05 am - 10:20 am Chairs: Ralph A. DeFronzo, MD • Peter J. Grant, MD

9:05 am Insulin Resistance in T2DM: Whole Body, Organ, Cellular, and Molecular Pathogenesis Ralph A. DeFronzo, MD Insulin Resistance and Myocardial Energy Metabolism: Implications for Therapy E. Dale Abel, MD, PhD 9:25 am Samuel Klein, MD

9:45 am Which Comes First: Insulin Resistance or Obesity?

10:05 am - 10:20 am Panel Discussion and Q&A

10:20 am - 10:50 am REFRESHMENT BREAK at the Exhibit Hall

Progress in Pediatric Obesity and T2D: New and Advanced Treatments Session 11

Chairs: Sonia Caprio, MD • Alan R. Sinaiko, MD 10:50 am - 12:05 pm

10:50 am GLP-1 RA for the Treatment of Youth Onset Obesity and T2D: From Fantasy to Reality Silva Arslanian, MD Achieving Metabolic Homeostasis in Youth with Obesity, Prediabetes/T2D and NAFLD, using Semaglutide 2, 4 mg. 11:10 am Sonia Caprio, MD

11:30 am Novel Treatments on the Horizon for Youth with Obesity, Fatty Liver & T2D

11:50 am - 12:05 pm Panel Discussion and Q&A

12:05 pm - 1:05 pm**LUNCH BREAK**

Product Theater Hall Lunch Session 12:15 pm - 1:00 pm Non-CME

Mounjaro® (tirzepatide)

Steven Edelman, MD Supported by Lilly

Session 12 Joint Session with Metabolism

1:00 pm - 2:20 pmChairs: Christos S. Mantzoros, MD, PhD • Tracey L. McLaughlin, MD, MS 1:00 pm Introduction and Updates on The Metabolism Journal Christos S. Mantzoros, MD, PhD

1:05 pm Vascular Mineralocorticoid Receptors, Vascular Insulin Sensitivity in Cardiometabolic Disorders:

From Physiology to Clinical Relevance Michael A. Hill, PhD Metabolic Surgery Important Role in the Comprehensive Management of Metabolic Diseases Geltrude Mingrone, MD, PhD 1:25 pm

Cardiorenal Protection with SGLT2 Inhibitors: From Physiology to Clinical Outcomes 1:45 pm

to the Future in Heart Failure and Diabetic Kidney Disease David Cherney, MDCM, PhD

Panel Discussion and Q&A 2:05 pm - 2:20 pm



FRIDAY, DECEMBER 8 (Cont.)

Session 13	A Glimpse into	The Future - What	's in the Pipeline?

2:20 pm - 3:20 pm Chairs: Ralph A. DeFronzo, MD • Christos S. Mantzoros, MD, PhD

2:20 pm Boaz Hirshberg, MD Regeneron 2:35 pm Esperion Stephen L. Pinkosky, PhD Joseph K. Belanoff, MD 2:50 pm Corcept

3:05 pm - 3:20 pmPanel Discussion and Q&A

3:20 pm - 4:35 pmREFRESHMENT BREAK at the Exhibit Hall

3:40 pm - 4:25 pm **Non-CME Education Product Theater Hall Reception Session**

The Evolving Cardiovascular-Renal-Metabolic Paradigm: How Can Healthcare Systems Better Match Science?

Supported by **Boehringer Ingelheim**

*Refreshments will be served

Pamela Kushner, MD

David Cherney, MD

Yehuda Handelsman, MD



Session 14 Contemporary Management of Diabetes

Chairs: George Grunberger, MD • Paul S. Jellinger, MD 4:35 pm - 6:15 pm

Molecular Mechanisms by Which Glucagon Regulates Hepatic Mitochondrial Oxidation 4:35 pm

and Gluconeogenesis — Implications for Dual and Triple GLP-1 Analogs

Incretins in Diabetes- The New, the Newest and the Future 4:55 pm

5:15 pm CGM in People Without Diabetes

5:35 pm Overcoming Clinical Inertia: The COORDINATE- Diabetes Example

5:55 pm - 6:15 pm Panel Discussion and Q&A

Supported by Lexicon Pharmaceuticals

Gerald I. Shulman, MD, PhD

Tracey L. McLaughlin, MD, MS

Richard E. Pratley, MD

Jennifer B. Green, MD

Yehuda Handelsman, MD

Matthew J. Budoff, MD

Stephen J. Greene, MD

Darren McGuire, MD, MHSc



6:15 pm - 7:30 pm

Dinner CME Symposium

Breaking New Ground in Heart Failure Treatment

Chairs: Matthew J. Budoff, MD • Yehuda Handelsman, MD

Introduction & Pre CME Questions 6:15 pm 6:25 pm Prevalence, Pathophysiology and Morbidities of Heart Failure 6:40 pm Contemporary Approach to Management of Heart Failure

Sotagliflozin: The Next Generation of Heart Failure Management 6:55 pm

7:10 pm Panel Discussion, Q&A, and Post-CME: Advancing the Care of Heart Failure- Relationship to CKD

Panel: Matthew J. Budoff, MD • Stephen J. Greene, MD • Darren McGuire, MD, MHSc • Matthew R .Weir, MD

Moderator: Yehuda Handelsman, MD

Post-CME Questions & Concluding Remarks 7:25 pm

7:30 pm Adjourn

Abstract Oral Presentation 7:30pm - 9:00 pm

Cheese and Wine

Chair: Zachary T., Bloomgarden, MD

Abstract Committee: Ralph A. DeFronzo, MD • Vivian A. Fonseca, MD • George Grunberger, MD Derek LeRoith, MD • Christian W. Mende, MD • Richard E. Pratley, MD • Matthew R. Weir, MD

Abstracts are published in Metabolism - Editor-in-Chief: Christos S. Mantzoros, MD, PhB





SATURDAY, DECEMBER 9, 2023

7:00 am Registration

7:00 am - 7:45 am **Breakfast Session Non-CME Education Product Theater Hall**

Evolving Perspectives in Hyperglycemia Secondary to Hypercortisolism: A Retrospective Look

Supported by Corcept

Daniel Einhorn, MD

Ralph A. DeFronzo, MD



Yehuda Handelsman, MD



Stephen J. Greene, MD

Gregg C. Fonarow, MD

8:00 am — 8:05 am Oral Abstract Award Presentation	Zachary T. Bloomgarden, MD

8:05 am - 8:20 am Summary of Day 2 and Pre-CME Questions Zachary T. Bloomgarden, MD

Session 15 Cardiomyopathy & Heart Failure - Panel Session

8:20 am - 10:00 am Chairs: Nikolaus Marx, MD • Mikhail N. Kosiborod, MD

8:20 am Contemporary Approach to Cardiac Amyloidosis Michelle M. Kittleson, MD, PhD Uri Elkayam, MD

Cardiomyopathy and Pregnancy The Role of Diuretics in Heart Failure

Management of Heart Failure: Bridging the Gap Between Evidence and Practice

Discussions and Q&A

10:00 am

REFRESHMENT BREAK 10.00 am - 10.10 am

Session 16 CVOT & Guidelines

10:10 am - 11:00 am Chairs: Peter J. Grant, MD • Matthew R. Weir, MD

10:10 am CVOTs Update Mikhail N. Kosiborod, MD 2023 ESC Diabetes and Cardiovascular Disease Guidelines 10:30 am Nikolaus Marx, MD

10:50 am - 11:00 am Panel Discussion and Q&A

Gerald Reaven Distinguished Leader in Insulin Resistance 2023 Award **Session 17**

11:00 am Award Presentation by Peter J. Grant, MD • Samuel Klein, MD

11:05 am Insulin Resistance and its Outcomes in T2DM: A Historical and Epidemiological Perspective

11:35 am - 11:45 am A&Q

Paul Zimmet, MD, PhD



11:45 am - 12:45 pm **LUNCH & CHECK-OUT BREAK**

Product Theater Hall 11:55 am - 12:40 pm Lunch Session Non-CME

Innovation and Improved Outcomes with Abbott Diabetes Care

Supported by Abbott

George Grunberger, MD



Fat Mass and Adipocyte **Session 18**

Chairs: Richard E. Pratley, MD • Bart Staels, PhD 12:45 pm - 1:35 pm

12:45 pm The Role of Relative Fat Mass- RFM vs. BMI Predicting T2D, Heart Failure and CVD Richard N. Bergman, PhD 1:05 pm GIP-R Action in the Adipocyte Philipp E. Scherer, PhD

1:25 pm - 1:35 pmPanel Discussion and Q&A



SATURDAY, DECEMBER 9 (Cont.)

Session 19	Contemporary Approach to	Obesity - Panel Session		
1:35 pm — 2:55 pm	Chairs: Samuel Klein, MD ● W. Timothy Garvey, MD			
1:35 pm	Nutrient-Stimulated Hormone-Based Therapies for Obesity Treatment: Clinical Application and Pipeline Diets, Calorie Restrictions vs Intermittent Fasting Addressing The Energy Balance Model Weight and Weight Changes Impact on CV Risk Discussions and Q&A: Does The Availability of Effective Pharmacotherapy To Treat Obesity Negates The Need For The Other Treatment Options?			Ania M. Jastreboff, MD, PhD Eric Ravussin, PhD Neha J. Pagidipati, MD, MPH
2:55 pm	·			
2:55 pm — 3:10 pm	REFRESHMENT BREAK			
Session 20	Not All Diabetes — is Type 2	2 DM		
3:10 pm — 4:00 pm	Chairs: Paul Zimmet, MD, PhD • Zacho	ary T. Bloomgarden, MD		
3:10 pm 3:30 pm 3:50 pm — 4:00 pm	Diabetes Secondary to Pancreatitis 2023 Prevention and Management of Panel Discussion and Q&A	T1D- The New Reality		Mark O. Goodarzi, MD, PhD George Grunberger, MD
Session 21	ASCVD Imaging - Panel Sessi	ion		
4:00 pm — 5:00 pm	Chairs: Matthew J. Budoff, MD • Norm	nan E. Lepor, MD		
4:00 pm	Imaging in Predicting Subacute Athero CTA in Predicting Survival- the CONFIR Association of Coronary Artery Calciun Comparing Plaques in Patients with & Discussions and Q&A	M Registry n & Spine Bone Density	Matthew J. Bu	doff, MD • Michael J. Blaha, MD, MPH
5:00 pm				
Session 22 5:00 pm — 6:00 pm	Concurrent Sessions: Clinica	ıl Workshop	Wine and Cheese	
	Lipids Diabetes HTN/CKD	Paul S. Jellinger, MD & Po George Grunberger, MD Christian W. Mende, MD		Sierra C/D (Lecture Hall) Sierra B Hiro
6:00 pm	Adjourn			

21ST WCIRDC PROGRAM COMMITTEE

Yehuda Handelsman, MD, Chair ● Matthew Budoff, MD ● Zachary Bloomgarden, MD, MACE ● Sonia Caprio, MD

Robert Chilton, DO ● Ralph DeFronzo, MD ● Vivian Fonseca, MD ● Tim Garvey, MD ● Peter Grant, MD ● Jennifer Green, MD

George Grunberger, MD ● Chris Guerin, MD ● Paul Jellinger, MD ● Mikhail Kosiborod, MD

Ronald Krauss, MD ● Norman Lepor, MD ● Nikolaus Marx, MD ● Tracy McLaughlin, MD, MS ● Derek Leroith, MD, PhD

Christos Mantzoros, MD, PhD • Chris Mende, MD • Erin Michos, MD, MHS • Jorge Plutzky, MD • Richard Pratley, MD • Arun Sanyal, MD, MBBS

Phil Scherer, PhD ● Alan Sinaiko, MD ● Bart Staels, PhD ● Pam Taub, MD ● Matthew Weir, MD ● Paul Zimmet, MD, PhD ● Renee Asp, BS



FACULTY 2023



Yehuda Handelsman, MD, Chair FACP, FNLA, FASPC, FAHA, MACE Medical Director & Principal Investigator The Metabolic Institute of America Chair Scientific Advisory Board DCMi- Diabetes CardioRenal & Metabolism Institute Chair & Program Director 21st WCIRDC



E. Dale Abel, MD, PhD
William S. Adams Distinguished Professor of Medicine
Chair and Executive Medical Director
Department of Medicine

Tarzana, California

David Geffen School of Medicine and UCLA Health Los Angeles, CA

Arthur S. Chairman a

Arthur S. Agatston, MD, FACC, FSCCT

Arthor S. Aguston, MD, FACC, FSCCT
Chairman and CEO
The Agaston Center for Preventive Medicine
Clinical Professor of Medicine
FIU Herbert Wertheim College of Medicine
Clinical Associate Professor of Medicine,
University of Miami Miller School of Medicine
Medical Director of Wellness and Prevention
Baptist Health South Florida
Miami Beach, Florida



Silva Arslanian, MD

Richard L. Day Professor of Pediatrics
Pediatric Endocrinology
Metabolism & Diabetes Mellitus
University of Pittsburgh School of Medicine
Director, Pediatric Clinical & Translational
Research Center
Scientific Director, Center for Pediatric Research
in Obesity & Metabolism
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania



Joseph K. Belanoff, MD

Chief Executive Officer, President and Director Co-founder, Corcept Therapeutics Redwood, California



Richard N. Bergman, PhD

Alfred Jay Firestein Chair in Diabetes Research Professor, Department of Biomedical Sciences and Medicine Cedars-Sinai Medical Center Director Diabetes and Obesity Wellness and Research Center Professor-in-Residence, UCLA Professor Emeritus USC Los Angeles. California



Michael Joseph Blaha, MD, MPH

Professor of Cardiology and Epidemiology, Johns Hopkins University School of Medicine Director of Clinical Research, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease Baltimore, Maryland



Zachary T. Bloomgarden, MD, MACE

Clinical Professor, Department of Medicine Icahn School of Medicine at Mount Sinai Editor, The Journal of Diabetes New York, New York



Matthew J. Budoff, MD, FACC, FAHA

Professor of Medicine
David Geffen School of Medicine at UCLA
Endowed Chair of Preventive Cardiology
Lundquist Institute
Program Director of Cardiac CT
Division of Cardiology Harbor-UCLA Medical Center
Torrance, California



Sonia Caprio, MD

Professor of Pediatric Endocrinology Yale University School of Medicine New Haven, Connecticut



David Cherney, MD CM, PhD, FRCP(C)

Professor of Medicine, University of Toronto Clinician Scientist, Division of Nephrology University Health Network Director, Renal Physiology Laboratory University Health Network Senior Scientist, Toronto General Hospital Research Institute Toronto, Ontario



Robert J. Chilton, DO, FACP, FACC FAHA, MACOI, FASCAI

Professor of Medicine, Division of Cardiology Associate Program Director, Interventional Cardiology The University of Texas Health Science Center San Antonio, Texas



Ralph A. DeFronzo, MD

Professor of Medicine
Chief, Diabetes Division
The University of Texas Health Science Center
Deputy Director, Texas Diabetes Institute
San Antonio, Texas



Uri Elkavam. MD

Professor of Medicine (Cardiology)
Obstetrics and Gynecology
Director of the Maternal Cardiology Program
Los Angeles, California



Keith C. Ferdinand, MD, FACC, FAHA FASPC. FNLA

Gerald S. Berenson Chair in Preventative Cardiology Professor of Medicine, Tulane University School of Medicine New Orleans, Louisiana



Gregg C. Fonarow, MD, FACC, FAHA, FHFSA

Eliot Corday Professor of Cardiovascular Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director, UCLA Preventative Cardiology Program Los Angeles, California



Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology Assistant Dean for Clinical Research Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Medical Center New Orleans, Louisiana



Emily J. Gallagher, MD, PhD

Associate Professor, Division of Endocrinology
Diabetes and Bone Disease
Associate Program Director, Internal Medicine
Residency Program,
Director ABIM Research Pathway for the Internal
Medicine Residency Program,

Medicine Residency Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY



W. Timothy Garvey, MD

Birmingham, Alabama

Charles E. Butterworth, Jr., Professor and University Professor Department of Nutrition Sciences University of Alabama at Birmingham Director, UAB Diabetes Research Center



Mark O. Goodarzi, MD, PhD, FACP

Professor of Medicine
Eris M. Field Chair, Diabetes Research
Director, Endocrine Genetics Laboratory
Cedars-Sinai Medical Center
Los Angeles, California



Peter J. Grant, MD, FRCP, FMedSci

Professor of Medicine and Diabetologist Honorary Consultant Physician Leeds Teaching Hospitals NHS Trust Division of Cardiovascular & Diabetes Research University of Leeds Leeds, United Kingdom

FACULTY 2023



Jennifer B. Green, MD
Professor of Medicine, Division of Endocrinology
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina



Stephen J. Greene, MD
Assistant Professor of Medicine (Cardiology)
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina



George Grunberger, MD, FACP, MACE
Chairman, Grunberger Diabetes Institute
Clinical Professor, Internal Medicine and
Molecular Medicine & Genetics
Wayne State University School of Medicine
Professor, Internal Medicine Oakland University William
Beaumont School of Medicine
Visiting Professor, Internal Medicine
First Faculty of Medicine, Charles University, Prague,
Czech Republic
Bloomfield Hills, Michigan



Chris K. Guerin, MD, FACE, FNLA
Medical Director, Diabetes Education Services and the
Diabetes Service Line
Past Chief, Division of Internal Medicine and Chair
Department of Medicine, Tri-City Medical Center
Founder, Advanced Metabolic Care and Research
San Diego, California



Michael A. Hill, PhD
Investigator, Dalton Cardiovascular Research Center
Professor, Department of Medical Pharmacology
and Physiology
University of Missouri School of Medicine
Columbia, Missouri



Boaz Hirshberg, MD Senior Vice President, Clinical Sciences General Medicine, Regeneron Tarrytown, New York



Ania M. Jastreboff, MD, PhD
Associate Professor of Medicine & Pediatrics
Endocrinology & Pediatric Endocrinology
Director, Yale Obesity Research Center (Y-Weight)
Co-Director, Yale Center for Weight Management
Yale University School of Medicine
New Haven, Connecticut



Paul S. Jellinger, MD, MACE Professor of Clinical Medicine Voluntary Faculty, University of Miami Miller School of Medicine The Center for Diabetes & Endocrine Care Hollywood, Florida



Michelle M. Kittleson, MD, PhD Professor of Medicine (Cardiology) Smidt Heart Institute Cedars-Sinoi Medical Center Los Angeles, CA



Samuel Klein, MD
Director, Center for Human Nutrition
Chief Scientific Officer
Sansum Diabetes Research Institute
Washington University School of Medicine
Saint Louis, Missouri



Rohit Kohli, MBBS, MS
Chief, Division of Gastroenterology, Hepatology
and Nutrition
Associate Director, The Saban Research Institute
at Children's Hospital Los Angeles
Professor of Pediatrics, Keck School of Medicine of USC
Los Angeles, California



Mikhail N. Kosiborod MD, FACC, FAHA
Vice President of Research, Saint Luke's Health System
Executive Director, Cardiometabolic Center Alliance
Director of Cardiometabolic Research and Co-Director
of the Haverty Cardiometabolic Center of Excellence at
Saint Luke's Mid America Heart Institute
Professor of Medicine, University of Missouri
Inaugural recipient of the Ben McCallister, MD
Endowed Chair in Cardiovascular Research at
Saint Luke's Health System.
Kansas City, Missouri



Ronald M. Krauss, MD
Professor of Pediatrics and Medicine, UCSF
Adjunct Professor, Department of Nutritional Sciences,
UC Berkeley
Berkeley, California



Rohit N. Kulkarni, MD, PhD
Margaret A. Congleton Chair and Co-Head
Islet & Regenerative Biology, Joslin Diabetes Center
Professor of Medicine, Harvard Medical School
Principle Faculty, Harvard Stem Cell Institute
Boston, Massachusetts



Norman E Lepor, MD, FACC, FAHA
Founder and Director, National Heart Institute
Past President, California Chapter, American
College of Cardiology
Clinical Professor of Medicine - Geffen School of
Medicine-UCLA 2010-2023
Attending Cardiologist, Smidt Cedars-Sinai Heart Institute
Los Angeles, CA



Derek LeRoith, MD, PhD, FACP
Professor of Medicine, Director of Research
Division of Endocrinology, Diabetes & Bone Disease
Department of Medicine
Icahn School of Medicine at Mt. Sinai
New York, New York



Rohit Loomba, MD, MHSc Professor of Medicine Chief, Division of Gastroenterology and Hepatology Director, NAFLD Research Center UC San Diego School of Medicine San Diego, California



Christos S. Mantzoros, MD, DSc, PhD h.c. mult.
Professor of Medicine, Harvard Medical School and
Boston University School of Medicine
Chief of Endocrinology, Diabetes, and Metabolism
Boston VA Healthcare System
Director of Human Nutrition
Beth Israel Deaconess Medical Center
Editor-in-Chief, Metabolism, Clinical & Experimental
Harvard, Massachusetts



Seth S. Martin, MD, MHS, FACC, FAHA, FASPC Professor of Medicine (Cardiology) Johns Hopkins Hospital Johns Hopkins University School of Medicine Baltimore, Maryland



Nikolaus Marx, MD, FESC, FAHA
Director of Medical Clinic I - Cardiology, Angiology
and Internal Intensive Care Medicine
University Hospital RWTH Aachen
Professor of Medicine - Cardiology
RWTH Aachen University
Aachen, Germany

Darren McGuire, MD, MHSc

Distinguished Teaching Professor of



Medicine with Tenure
Jere H. Mitchell, M.D. Distinguished Chair in
Cardiovascular Science
Division of Cardiology; Department of Internal Medicine
University of Texas Southwestern Medical Center
Lead Physician, Parkland Health Cardiology Clinics
Deputy Editor, Circulation
Dallas, Texas



Tracey L. McLaughlin, MD, MS
Professor of Medicine, Division of Endocrinology
Clinician Investigator
Stanford University School of Medicine
Stanford, California



Christian W. Mende, MD, FACP, FACN, FASN, FAHA Clinical Professor of Medicine University of California San Diego La Jolla, California



FACULTY 2023



Erin D. Michos, MD, MHS FAHA, FACC, FASE, FASPC

Director of Women Cardiovascular Health Research Associate Director of Preventive Cardiology Division of Cardiology Johns Hopkins University School of Medicine Director, IMPACT Center at JHU Co-Editor in Chief American Journal of Preventive Cardiology Baltimore, Maryland



Geltrude Mingrone, MD, PhD

Associate Professor of Internal Medicine
Catholic University, School of Medicine
Chief, Division of Obesity and Related Disorders
Policlinico A. Gemelli Hospital Rome, Italy
Professor of Diabetes and Nutrition
King's College London,
London, UK



Neha J. Pagidipati, MD, MPH

Associate Professor, Division of Cardiology
Duke University School of Medicine
Director, Duke Cardiometabolic Prevention Clinic
Duke Clinical Research Institute
Durham, North Carolina



Stephen Pinkosky, PhD

Vice President, Head of Discovery and Early Development, Esperion Arbor, Michigan



Jorge Plutzky, MD

Director, Preventive Cardiology, Brigham and Women's Hospital Boston, Massachusetts



Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research Medical Director, AdventHealth Diabetes Institute Senior Investigator and Diabetes Program Lead AdventHealth Translational Research Institute Adjunct Professor of Medicine Johns Hopkins University School of Medicine Orlando, Florida



Eric Ravussin, PhD

Baton Rouge, Lousiana

Director, Nutrition Obesity Research Center
Douglas L. Gordon Chair in Diabetes and Metabolism
Boyd Professor and Associate Executive Director
for Clinical Science
Metabolic Chambers Human Translational Physiology
Pennington Biomedical Research Center
Louisiana State University



Paul D. Rosenblit, MD, PhD, FACE, FNLA

Clinical Professor, Medicine
Division of Endocrinology, Diabetes, Metabolism
University of California, Irvine School of Medicine
Director, & Site Principal Investigator
Diabetes / Lipid Management & Research Center
Huntington Beach, California



Peter Rossing, MD, DMSc

Professor Department of Clinical Medicine University of Copenhagen Steno Diabetes Center Copenhagen Herlev, Denmark



Philipp E. Scherer, PhD

Professor, Department of Internal Medicine Gifford O. Touchstone Jr. and Randolph G. Touchstone Distinguished Chair in Diabetes Research Director, Touchstone Diabetes Center The University of Texas, Southwestern Medical Center Dallas, Texas



Gerald I. Shulman, MD, PhD, MACP, MACE, FRCP

George R. Cowgill Professor of Medicine (Endocrinology)
Professor of Medicine
and Cellular & Molecular Physiology
Co-Director Yale Diabetes Research Center
Investigator Emeritus, Howard Hughes Medical Institute
New Haven, Connecticut



Alan R. Sinaiko, MD

Professor Emeritus, Department of Pediatrics Division of Pediatric Nephrology University of Minnesota Medical School Pediatrics and Division of Epidemiology School of Public Health Minneapolis, Minnesota



Bart Staels, PhD

Co-founder of GENFIT
Chairman of the Scientific Advisory Board
Full Professor, Faculty of Pharmacy, University de Lille
Director, Inserm UMR1011, Institut Pasteur de Lille
Lille, France



Pam R. Taub, MD, FACC, FASPC

Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center Professor of Medicine Division of Cardiovascular Medicine UC San Diego Health System La Jolla, California



Muthiah Vaduganathan, MD, MPH, FACC, FHFA

Cardiologist and Clinical Trialist
Brigham and Women's Hospital and
Harvard Medical School
Co-director, Center for
Cardiometabolic Implementation Science
Boston, Massachusetts



Matthew R. Weir, MD

Professor and Chief Division of Nephrology
Department of Medicine
University of Maryland
School of Medicine
Baltimore, Maryland



Nathan D. Wong, PhD, MPH, FACC FAHA, FNLA, MASPC

Professor and Director
Heart Disease Prevention Program
Division of Cardiology, University of California, Irvine
Past President, American Society
for Preventive Cardiology
Irvine, California



Hussein Yassine, MD

Kenneth and Bette Volk Endowed Professor of Neurology Associate Professor, Department of Medicine Keck School of Medicine of the University of Southern California Los Angeles General Medical Center Los Angeles, California



Paul Zimmet, MD, PhD

Professor of Diabetes, Monash University
Honorary President, International Diabetes Federation
Co-Director, The Sagol Center for Epigenetics of
Metabolism and Ageing, Telaviv Medical Center
Doctor of Laws, Honoris Causa (Monash)
Doctor Philosophiae Honoris Causa (Tel Aviv University)
Honoris Causa Doctoris, Complutense University (Madrid)
Doctor of the University, Honoris Causa (Adelaide)
Doctor of Philosophy, Umea University (Sweden)
Melbourne, Australia

REGISTRATION INFORMATION

www.wcir.org/registration

Email info@tmioa.com To register by phone (818) 342-1889

All 21st WCIRDC participants must be vaccinated in order to attend the live in person meeting. For further information please contact info@tmioa.com

CME Accreditation:

For CME questions related to WCIRDC, please contact our CME Coordinator Renee Asp at renee@aspencmehelp.com

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Designation Statement:

PESI Inc. has designated this Live activity for a maximum of 26.75 AMA PRA Category 1 Credit(s) TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.

MOC Points with ABIM:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points of Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Total qualifying MOC points 26.75

International CME:

International Physicians are formally eligible for AMA PRA Category 1 Credit $^{\text{TM}}$.

Physician Assistants:

AAPÅ accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit $^{\text{TM}}$ for the PRA from organizations accredited by ACCME.

Nurses:

For the purpose of re-certification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

Pharmacists

For the purpose of re-certification, the American Council of Pharmacy Education accepts AMA PRA Category 1 CreditTM issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CDE

The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. Total qualifying continuing education hours 26.75

Registered Dietitians

For the purpose of re-certification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 CreditTM.

Satisfactory Completion for Credits

All attendees must have completed and submitted an online course attendance/evaluation immediately following onsite attendance. Each session claimed for credit must be attended in its entirety. Attendees will be able to print a certificate of attendance following the submission of online evaluation. Physician certificates of credit will be emailed two to three weeks after the CME activity.

* For Physicians to have credits recorded to ACCME PARs for licensing and certification board records, physicians must provide: 1) State of licensure, 2) license ID #, 3) Birthdate - month and day, and 4) ABIM #.

Enduring / On-Demand CME Activity

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Designation Statement

PESI Inc. has designated this Enduring activity for a maximum of 26.75 AMA PRA Category 1 Credit(s) $^{\text{TM}}$. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Available online at www.wcir.org from December 10, 2023 through March 10, 2024.



2023 PARTNERS

ASSOCIATED ORGANIZATIONS

Premier Associated Organizations

- Clinical Association of California Endocrinologists (CACE)
- California Chapter American College of Cardiology (CAACC)
- American Society for Preventive Cardiology (ASPC)

Associated Organizations

- American Society of Endocrine Physician Assistants (ASEPA)
- American Society of Preventive Oncology (ASPO)
- Association of Diabetes Care and Education Specialists (ADCES)
- Endocrine Nurses Society (ENS)
- Family Heart Foundation
- International Federation for Surgery of Obesity & Metabolic Disorders (IFSO)

- Israel Endocrine Society (IES)
- Point of Care Network (POCN)
- Society for Endocrinology (SFE)
- Societa Italiana Endocrinologia (SIE)
- World Obesity Federation (WOF)
- National Kidney Foundation of America (NKFA)
- Korean Heart Rhythm Society (KHRS)

MEDIA PARTNERS

Premier Media Partners

- Metabolism (Elsevier)
- Healio Cardiology Today & Endocrine Today
- Closed Concerns
- American Journal of Cardiology (Elsevier)
- American Journal of Managed Care (MJH Life Sciences)
- HCPLive Network (MJH Life Sciences)

Media Partners

- Elsevier
- Diabetes and Vascular Research (Sage)
- Frontiers in Clinical Diabetes and Healthcare
- The Journal of Cardiovascular Ageing
- MJH Life Sciences
- Journal of Diabetes
- Journal of Clinical Medicine
- Metabolism and Target Organ Damage
- Nutrients Open Access
- CN1699 Media
- ConferenceLocate.com
- Connected health

- Diabetes in Control
- Endocrine Web
- Endocrinology Network
- MDPHournal
- MEDTube
- OAE Publishing Inc.
- PharmaVoice
- Physician's Weekly
- Practical Cardiology
- VenueDir
- VP Vessel Plus

HILLYWOUL

THE INTERNATIONAL COMMITTEE FOR INSULIN RESISTANCE GRATEFULLY ACKNOWLEDGES

EDUCATIONAL GRANT

ASTRAZENECA LEXICON PHARMACEUTICALS BAYER

BOEHRINGER INGELHEIM-LILLY

AMGEN

ESPERION THERAPEUTICS

CORPORATE SUPPORT EMERALD LEVEL

















The 8th Annual Heart in Diabetes

Where the heart, kidney, and diabetes meet in clinical practice.

SAVE-THE-DATE June 7 -9, 2024

Hilton Philadelphia at Penn's Landing

201 S. Christopher Columbus Blvd. Philadelphia, PA 19106

JOIN US FOR ANOTHER GROUNDBREAKING CME CONFERENCE.









heartindiabetes.com

SAVE THE DATE | December 12-14, 2024



World Congress Insulin Resistance



DIABETES & CARDIOVASCULAR DISEASE



Exploring New Frontiers in Metabolism - Tomorrow's Clinical Science Today

NEXT YEAR!



Hilton Universal

555 Universal Hollywood Dr. Universal City, CA 91608











@wcirdc

wcir.org







SUPPORT - REGISTRATION - ACCOMMODATIONS - EXHIBITION 818.342.1889 | 818.342.1538 | info@tmioa.com www.wcir.org

> Metabolic Endocrine Education Foundation (MEEF) 638 Lindero Canyon Dr Suite #380 Oak Park, CA 91377